Drugs.com - Monthly Update June 2025
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Drugs.com - Monthly Update June 2025
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
This is the June 2025 edition of the Drugs.com Monthly Update. We cover five significant FDA approvals that are transforming patient care across multiple therapeutic areas.
Dupixent (dupilumab), newly approved for treating bullous pemphigoid in adults—a painful autoimmune skin disorder primarily affecting patients over 65.
Mavyret (glecaprevir/pibrentasvir) for acute hepatitis C virus treatment in children as young as 3 years old.
Yeztugo (lenacapavir), a groundbreaking twice-yearly injectable HIV prevention therapy offering a 99.9% effectiveness rate in clinical trials.
Enflonsia (clesrovimab-cfor), a new RSV prevention option for neonates and infants that provides season-long protection with a single injection.
Ibtrozi (taletrectinib), an oral targeted therapy approved for ROS1-positive non-small cell lung cancer in patients with locally advanced or metastatic disease.
Chapters:
- (00:00) - Intro
- (00:24) - Overview
- (00:45) - Dupixent
- (01:38) - Mavyret
- (02:14) - Yeztugo
- (03:14) - Enflonsia
- (03:54) - Ibtrozi
- (04:26) - Outro
- X, Facebook, Youtube
- Signup to our newsletters
- Download the app